Clinical trials: Azacitidine
Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.
- Trial name
- NCT05320640
- Testing
- Chidamide, Decitabine, Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment.
- Conditions
- Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04055844
- Testing
- Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myeloproliferative Neoplasm
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
This phase I trial studies the side effects and best dose of pacritinib when given together with venetoclax and azacitidine in treating patients with accelerated and blast phase myeloproliferative neoplasms (MPN-AP/BP).
- Trial name
- NCT07679334
- Testing
- Pacritinib, Venetoclax, Azacitidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT01358734
- Testing
- Azacitidine, Lenalidomide, Best Supportive Care (BSC)
- Where
- 30 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Celgene
Acute Myeloid Leukemia (AML)
"InDACtion" vs "3+7" Induction in AML
Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last…
- Trial name
- NCT02172872
- Testing
- standard combination chemotherapy, decitabine
- Where
- 53 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 606 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT03843528
- Testing
- Vorinostat, Azacitidine Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins All Children's Hospital
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases.
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT00351975
- Testing
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
- Trial name
- NCT06445907
- Testing
- Azacitidine, Venetoclax, Q702
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00454480
- Testing
- alemtuzumab, arsenic trioxide, azacitidine
- Where
- 96 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- The University of New South Wales
Leukemia
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
This clinical research study is made up of 2 phases. The goal of Phase 1 of the study is to test the safety of the combination of omacetaxine and decitabine and to find the best dose to give to future patients.
- Trial name
- NCT02141477
- Testing
- Omacetaxine, Decitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- Trial name
- NCT01378416
- Testing
- Decitabine (Dacogen)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Eisai Inc.
Pancreas Cancer
Azacitidine and Pembrolizumab in Pancreatic Cancer
The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer.
- Trial name
- NCT03264404
- Testing
- Pembrolizumab, Azacitidine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Susan E. Bates
Peripheral T-cell Lymphoma Targeted Therapy
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with…
- Trial name
- NCT05678933
- Testing
- Azacitidine, Chidamide, Cyclophosphamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Myelodysplastic Syndromes(MDS)
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in…
- Trial name
- NCT05709093
- Testing
- Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
- Where
- 44 sites in China
- Volunteers
- 10 people
- Sponsor
- TJ Biopharma Co., Ltd.
Hematopoietic System--Cancer
Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia
Hematopoietic stem cell transplantation (HSCT) is the only curative option for most of juvenile myelomonocytic leukemia (JMML). However, relapse after HSCT severely influence the long-term overall survival (OS).
- Trial name
- NCT03687463
- Testing
- Decitabine
- Volunteers
- 6 people
- Sponsor
- Capital Research Institute of Pediatrics
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥ 60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia.
- Trial name
- NCT00691938
- Testing
- LBH589, Decitabine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia (AML) in Remission
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who…
- Trial name
- NCT05404906
- Testing
- Azacitidine, Venetoclax, Supportive care
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia in Remission
Pilot Study of Reduced Venetoclax Exposure
Pilot Study of Reduced Venetoclax Exposure
- Trial name
- NCT07163793
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Northwell Health
Leukemia
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
The purpose of this study is to find out if patients older than 60, with acute myeloid leukemia, who are in complete remission following initial chemotherapy, will live longer and have a lower rate of leukemia relapse when…
- Trial name
- NCT00387647
- Testing
- Azacitidine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
AML (Acute Myelogenous Leukemia)
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
The combination of azacitidine and venetoclax is currently considered a therapeutic strategy innovative in AML through the addition of new compounds (triplet therapies), including inhibitors of the immune checkpoint inhibitors.
- Trial name
- NCT06874257
- Testing
- Laboratory tests and in vitro studies
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna